There are about 28871 clinical studies being (or have been) conducted in Canada. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
The purpose of the study is to evaluate the efficacy of cobitolimod treatment compared to placebo in inducing clinical remission, in participants with moderate to severe active left-sided UC and to evaluate the efficacy of cobitolimod maintenance treatment compared to placebo in inducing or maintaining clinical remission at week 52, in participants with clinical response at week 6 after induction treatment with cobitolimod.
There is emerging evidence suggesting that the pulmonary vasculature and right heart may play a role in the limitation of exercise capacity in healthy individuals. It is well established that aerobic training improves cardiovascular function. While the pulmonary system is integral to the function of the cardiopulmonary system, it has been traditionally accepted that lung function does not respond to exercise training. However, recent research suggests pulmonary vascular function adaptations may occur with aerobic training, and this may contribute to enhanced exercise tolerance. Research has highlighted that increased capillary blood volume (Vc) and diffusion capacity for carbon monoxide (DLCO) are correlated with higher cardiorespiratory fitness at rest. Additionally, endurance trained participants have increased exercise DLCO concomitant to higher resting Vc when compared to untrained participants, and during exercise this difference seems to be driven by higher membrane diffusing capacity (Dm), independent of Vc or VA (alveolar volume). Of importance is also the evidence that highlights endurance trained participants having reduced pulmonary arterial pressures at rest and during exercise. Reduced pulmonary arterial pressure in endurance trained participants despite endurance trained participants consistently displaying increased diffusion capacity/pulmonary perfusion at rest and during exercise suggests a lower threshold pressure for pulmonary capillary recruitment. Together, this cross-sectional evidence suggests improvements in the pulmonary circulation due to exercise training in order to facilitate gas exchange. Whether this apparent improvement in pulmonary circulation is due to enhanced pulmonary vascular function via NO mediated vasodilation must be determined experimentally. If sildenafil administration improves DLCO, Vc, and Dm, this would provide evidence that the NO mediated vasodilatory pathway plays a role in the regulation of vascular tone, function, and perfusion across the pulmonary vasculature. Should a larger response to sildenafil be observed in untrained persons, this would suggest better baseline vascular function in trained participants compared to untrained. This would provide strong evidence that aerobic training improves pulmonary vasculature function which is contrary to the conventional understanding of aerobic training on the cardiopulmonary system.
This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.
This is a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) subcutaneous injection every 4 weeks (SCq4w) in participants with a medically confirmed diagnosis of IgE-mediated peanut allergy.
Individuals on oral chemotherapy (OC) often face many challenges requiring adequate informational support, monitoring, and management. This pilot randomized control trial (RCT) aims to assess the feasibility, acceptability, and preliminary effects of a comprehensive OC intervention on medication adherence self-efficacy, medication adherence, and symptom distress.
A study designed to treat patients with back pain associated with degenerative lumbar disc disease.
This is an observational study to investigate if it is feasible to recruit 100 patients receiving radiotherapy (RT) to metastatic disease to wear Hexoskin and if Hexoskin will facilitate the monitoring, detection and early treatment of RT-related side effects.
Participants will be allocated to one of two experimental groups using a blocked randomization method; participants will be randomized within blocks such that an equal number are assigned to each treatment. Allocation proceeds by randomly selecting one of the orderings and assigning the next block of participants to study groups according to the specific sequence. Once participants are allocated to one block, each block will be randomly assigned to one of the two interventions. Participants will be randomly divided into one of two blocks, each containing a maximum of 75 participants. Possible treatment allocations within each block are (1) AABB, (2) BBAA, (3) ABAB, etc. This method ensures equal treatment allocation within each block. Each participant will then be assigned a number that will represent the participants' block as well as the participants' individual participant ID number (i.e., Participant '100-123' would be in the same group as participant '100-124'). Groups will be assigned using an Excel file to input participants into subsequent groupings and keep track of questionnaire submissions. At baseline, purpose-questionnaires will be distributed to both groups to assess history and experience with vaping and measure intention to vape less along with the "baseline self-reported questionnaires" that will be administered on Day 1 to all participants. At Day 7 (T1), respective participants will be emailed the attached video link and questionnaires and be instructed to complete the surveys after watching the participants' respective videos. The study intervention will be a single site trial delivered as a video link to the email provided by the participant; both intervention videos will play on YouTube and participants will be instructed to complete the surveys immediately after watching the video attached to the email sent to the participants. The participants will complete self-reported questionnaires at 3 follow-up periods after baseline in the 6-week protocol (all questionnaires will be sent by the student investigator (SI) to the email provided by the participants). Self-reported vaping behaviour questionnaires will be managed at baseline, Day 7 (T1), Day 30 (T2), and Day 45 (T3).
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
The investigators propose to examine a mismatch-based method of reconsolidation blockade for the treatment of psychological trauma in military personnel and Federal police officers. The standard reconsolidation blockade treatment (aka Reconsolidation Therapy) involves reactivating the trauma memory while under the influence of propranolol. The mismatch method of Reconsolidation Therapy will involve varying the contexts in which the weekly trauma memory retrieval will occur. This study will involve 10 visits (eligibility assessment, treatments, and follow-up visits) over a 6-month period for each participant. Treatments will be conducted once a week for a six-week period where the participant will take a dose of propranolol (or a placebo pill) 60 minutes prior to memory reactivation. The investigators hypothesize that reconsolidation blockade treatment will be as effective in treating PTSD among military personnel and Federal police officers, with the mismatch condition showing greater symptom improvement.